Two years after treatment, both girls show normal motor function and no signs of spinal muscular atrophy symptoms.

Those complexities extend to billing and coding. Sometimes navigating these complexities is a reason for patients who are ...

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Steven Levine, MD: Carrie, can you talk about what’s involved in procuring intranasal esketamine [Spravato], the various routes, whether that’s buy-and-bill or specialty pharmacy, and any of the ...

Drs Martin Rosenzweig and Samuel Nordberg share perspectives for integrated policymaking in behavioral health, as well as payer and provider collaboration for TRD.

Carrie Jardine leads a discussion on varying prior authorization policies for alternative therapies for TRD along with implications to patients.

Dr Patricia Ares-Romero and Dr Martin Rosenzweig discuss treatment strategies for TRD, including alternative therapies and explain current barriers within the healthcare system that inhibit access.

Furthest ahead in the pipeline is tolebrutinib, developed by Paris-based Sanofi to potentially treat SPMS, PPMS and relapsing forms of MS. The investigational agent is an oral central nervous system ...

The new J-code will become effective in January and will provide reimbursement when Exparel is used in the office setting and ...

Gilead Sciences’s decision to distribute HIV prevention drug lenacapavir made the news this month when they signed ...

Itovebi is approved to treat patients with PIK3CA-mutated HR-positive, HER2 negative metastatic breast cancer in combination ...